Initiator Pharma (Q3 review): Back in the clinic - Redeye

Redeye provides a research update following the Q3 report recently published by Initiator Pharma. While OPEX has slightly increased as the company initiates clinical activities again, the financials in the report did not contain any major surprises. Instead, the primary focus of the quarter has been on the reignited clinical development of pudafensine – now in the form of a phase IIa study in vulvodynia.

Länk till analysen i sin helhet: https://www.redeye.se/research/1140285/initiator-pharma-q3-review-back-in-the-clinic?utm_source=finwire&utm_medium=RSS